CRISPR-based innovations drive $21 billion in pharmaceutical licensing deals over five years, reveals GlobalData

The period from 2020 to 2022 witnessed a remarkable surge in deal worth

Celanese and Secarna Pharmaceuticals collaborate for RNA research for antisense therapies

Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes

Novo Nordisk, Eli Lilly record growth in Q2 driven by obesity, diabetes drug sales

Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion

Lilly's phase 2 retatrutide results show the investigational molecule achieved up to 17.5% mean weight reduction

Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program

50% of heart attacks now happens in Indians below 50 years: says Expert

Younger Indians have a 10 times higher rate of heart attack

Phygital model of med-tech seems to be quite Promising: opines Expert

To address the preventive & primary healthcare delivery gaps in India

Novo Nordisk and Flagship Pioneering partner to create a portfolio of transformational medicines

Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases

Lupin and Yabao announce strategic partnership in China

The demand for high-quality paediatric medicines has been growing rapidly in China as a result of the government’s support and policy measures

Jardiance is first and only treatment approved in Europe for chronic heart failure

The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe